Approval · Notice of Compliance 13088 · 2012
EDARBI: Notice of Compliance 13088
Issued March 8, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13088
- Date
- March 8, 2012
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Angiotensin II AT1 Receptor Blocker
Products in this notice
Medicinal ingredients
- AZILSARTAN MEDOXOMIL 40 MG per TAB
- AZILSARTAN MEDOXOMIL 80 MG per TAB